Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent
September 15 2021 - 7:00AM
Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the
"Company”), today announced that the United States Patent and
Trademark Office has issued a notice of allowance for claims
related to the Company’s platform technology.
The patent, titled, “Methods of Treatment of
Infections Using Bacteria,” (Application No. 16/584,644) provides
broad protection for the application of the Company’s platform
technology alone and in combination with standards of care for the
treatment and inhibition of hepatitis B virus (HBV) and human
immunodeficiency virus (HIV) infections.
“We are delighted to expand our growing patent
estate and this notice of allowance provides further validation of
the novel approach of our Indaptus platform technology as it
relates to viral infections,” said Dr. Michael Newman, Founder and
Chief Scientific Officer of Indaptus Therapeutics.
“This notice of allowance gives us the
optionality to confidently pursue our technology in viral diseases
and/or to partner it for further development,” said Jeffrey
Meckler, Chief Executive Officer of Indaptus Therapeutics.
The Indaptus pipeline is rooted in the
hypothesis that highly efficient anti-tumor or anti-viral
immunotherapy will require safe activation of both innate and
adaptive immunity in both tumors or sites of infection, as well as
immune organs, and that this might be achieved with a
multi-targeted package of bacterial immune system activators, in
the form of attenuated, killed and intact, non-pathogenic bacteria
delivered intravenously.
Single agent therapeutics derived from the
Indaptus platform have produced significantly broader activity than
standard of care treatment in a pre-clinical model of chronic
hepatitis B infection, as well as single agent activity against
chronic HIV infection in a pre-clinical humanized mouse model.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than
a century of immunotherapy advances. The Company's approach is
based on the hypothesis that efficient activation of both innate
and adaptive immune cells and associated anti-tumor and
anti-viral immune responses will require a multi-targeted
package of immune system activating signals that can be
administered safely intravenously. Indaptus' patented
technology is composed of single strains of attenuated
and killed, non-pathogenic, Gram-negative bacteria, with
reduced i.v. toxicity, but largely uncompromised ability to
prime or activate many of the cellular components of innate
and adaptive immunity. This approach has led to broad
anti-tumor and anti-viral activity, including safe, durable
anti-tumor response synergy with each of five different classes of
existing agents, including checkpoint therapy, targeted
antibody therapy and low-dose chemotherapy in preclinical models.
Tumor eradication by Indaptus technology has demonstrated
activation of both innate and adaptive immunological memory
and, importantly, does not require provision of or targeting a
tumor antigen in pre-clinical models. Indaptus has carried out
successful GMP manufacturing of its lead clinical oncology
candidate, Decoy20, and is currently completing other IND enabling
studies.Forward-Looking Statements
This press release contains forward-looking statements with the
meaning of the Private Securities Litigation Reform Act. These
include statements regarding management's expectations, beliefs and
intentions regarding, among other things, our product development
efforts, business, financial condition, results of operations,
strategies, plans and prospects. Forward-looking statements can be
identified by the use of forward-looking words such as "believe",
"expect", "intend", "plan", "may", "should", "could", "might",
"seek", "target", "will", "project", "forecast", "continue" or
"anticipate" or their negatives or variations of these words or
other comparable words or by the fact that these statements do not
relate strictly to historical matters. Forward-looking statements
relate to anticipated or expected events, activities, trends or
results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these
statements are inherently subject to risks and uncertainties that
could cause our actual results to differ materially from any future
results expressed or implied by the forward-looking statements.
Many factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: Indaptus' plans to develop and potentially commercialize
its technology, the timing and cost of Indaptus' planned
investigational new drug application and any clinical trials, the
completion and receiving favorable results in any clinical trials,
Indaptus' ability to obtain and maintain regulatory approval of any
product candidate, Indaptus' ability to protect and maintain its
intellectual property and licensing arrangements, Indaptus' ability
to develop, manufacture and commercialize its product candidates,
the risk of product liability claims, the availability of
reimbursement, the influence of extensive and costly government
regulation, and Indaptus' estimates regarding future revenue,
expenses capital requirements and the need for additional financing
following the merger. These risks, as well as other risks are
discussed in the proxy statement/prospectus that was included in
the registration statement on Form S-4 filed with the SEC in
connection with the merger. All forward-looking statements speak
only as of the date of this press release and are expressly
qualified in their entirety by the cautionary statements included
in this press release. We undertake no obligation to update or
revise forward-looking statements to reflect events or
circumstances that arise after the date made or to reflect the
occurrence of unanticipated events, except as required by
applicable law.
Investor Contact:Will O'Connor Stern
IR +1 212-362-1200 will@sternir.com
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024